Impact of Patient Navigation on Timely Cancer Care: The Patient Navigation Research Program
Authors:
- Karen M. FreundKFKaren M. Freund
- Tracy A. BattagliaTBTracy A. Battaglia
- Elizabeth CalhounECElizabeth Calhoun
- Julie S. DarnellJDJulie S. Darnell
- Donald J. DudleyDDDonald J. Dudley
- Kevin FiscellaKFKevin Fiscella
- Martha L. HareMHMartha L. Hare
- Nancy LaVerdaNLNancy LaVerda
- Ji-Hyun LeeJLJi-Hyun Lee
- Paul LevinePLPaul Levine
- David M. MurrayDMDavid M. Murray
- Steven R. PatiernoSPSteven R. Patierno
Top Cited Papers
Open Access
- 14 June 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (6) , dju115
Abstract
Patient navigation is a promising intervention to address cancer disparities but requires a multisite controlled trial to assess its effectiveness. The Patient Navigation Research Program compared patient navigation with usual care on time to diagnosis or treatment for participants with breast, cervical, colorectal, or prostate screening abnormalities and/or cancers between 2007 and 2010. Patient navigators developed individualized strategies to address barriers to care, with the focus on preventing delays in care. To assess timeliness of diagnostic resolution, we conducted a meta-analysis of center- and cancer-specific adjusted hazard ratios (aHRs) comparing patient navigation vs usual care. To assess initiation of cancer therapy, we calculated a single aHR, pooling data across all centers and cancer types. We conducted a metaregression to evaluate variability across centers. All statistical tests were two-sided. The 10521 participants with abnormal screening tests and 2105 with a cancer or precancer diagnosis were predominantly from racial/ethnic minority groups (73%) and publically insured (40%) or uninsured (31%). There was no benefit during the first 90 days of care, but a benefit of navigation was seen from 91 to 365 days for both diagnostic resolution (aHR = 1.51; 95% confidence interval [CI] = 1.23 to 1.84; P < .001)) and treatment initiation (aHR = 1.43; 95% CI = 1.10 to 1.86; P < .007). Metaregression revealed that navigation had its greatest benefits within centers with the greatest delays in follow-up under usual care. Patient navigation demonstrated a moderate benefit in improving timely cancer care. These results support adoption of patient navigation in settings that serve populations at risk of being lost to follow-up.Keywords
This publication has 40 references indexed in Scilit:
- Analysis of combined data from heterogeneous study designs: an applied example from the patient navigation research programClinical Trials, 2012
- Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-upJNCI: Journal of the National Cancer Institute, 2012
- Patient Navigation to Increase Mammography Screening Among Inner City WomenJournal of General Internal Medicine, 2010
- Understanding the Processes of Patient Navigation to Reduce Disparities in Cancer Care: Perspectives of Trained Navigators from the FieldJournal of Cancer Education, 2010
- Patient Navigation: Development of a Protocol for Describing What Navigators DoHealth Services Research, 2010
- Cancer treatment adherence among low‐income women with breast or gynecologic cancerCancer, 2009
- Comprehensive Diagnostic Program for Medically Underserved Women With Abnormal Breast Screening Evaluations in an Urban PopulationMayo Clinic Proceedings, 2009
- National Cancer Institute Patient Navigation Research ProgramCancer, 2008
- Patient navigation: State of the art or is it science?Cancer, 2008
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986